Examkin

Question

Difficulty: MediumInfectious Diseases

A 56-year-old woman is evaluated in the hospital on the third day of her admission for acute complicated pyelonephritis. On presentation to the emergency department, she had severe right flank pain, a temperature of 39.2°C (102.6°F), and a blood pressure of 90/60 mm Hg. After initial intravenous fluid resuscitation, her hemodynamics normalized, and she was admitted to the medical ward. She was empirically started on intravenous cefepime and vancomycin. Today, the patient reports that her flank pain has nearly resolved. She has been afebrile for the past 24 hours and is tolerating a regular diet without nausea or vomiting. Her current blood pressure is 122/78 mm Hg and pulse is 76/min. Blood and urine cultures obtained on admission both grow Escherichia coli. Susceptibility testing indicates the isolate is resistant to ampicillin but susceptible to ceftriaxone, piperacillin-tazobactam, ciprofloxacin, and trimethoprim-sulfamethoxazole. Which of the following is the most appropriate next step in the management of this patient's infection?

  1. Switch to oral ciprofloxacinAnswer
  2. B
    Switch to intravenous ceftriaxone
  3. C
    Switch to oral amoxicillin
  4. D
    Discontinue vancomycin and continue intravenous cefepime
  5. E
    Continue intravenous cefepime and vancomycin

Answer

The most appropriate next step is to switch to oral ciprofloxacin.
The patient has acute complicated pyelonephritis with associated Gram-negative bacteremia. She has achieved clinical stability (afebrile for 24 hours, hemodynamically normal) and can tolerate an oral diet. The standard of care in this scenario is antimicrobial stewardship: transitioning from empiric, broad-spectrum intravenous antibiotics to a targeted, narrow-spectrum, highly bioavailable oral antibiotic based on susceptibility results. Fluoroquinolones (like ciprofloxacin) and trimethoprim-sulfamethoxazole have excellent oral bioavailability, achieving systemic levels nearly equivalent to intravenous dosing. This 'step-down' therapy facilitates prompt hospital discharge, minimizes the risk of nosocomial complications (such as central line infections or DVT from prolonged bed rest), and reduces healthcare costs without compromising clinical outcomes.

Step-by-Step Solution

1
Evaluate the patient's current clinical trajectory.
The patient is hemodynamically stable, has been afebrile for 24 hours, and is tolerating oral intake.
Clinical stability dictates the safety and timing of transitioning a patient from intravenous to oral antimicrobial therapy.
2
Review culture and susceptibility data.
The infection is caused by E. coli that is susceptible to ciprofloxacin, trimethoprim-sulfamethoxazole, and several intravenous cephalosporins, but resistant to ampicillin.
Therapy must be targeted to the specific organism to ensure efficacy while avoiding excessively broad-spectrum agents.
3
Select the optimal targeted regimen.
Switching to an oral highly bioavailable agent, such as ciprofloxacin, is indicated.
Ciprofloxacin achieves serum and tissue concentrations comparable to intravenous administration, making it ideal for step-down therapy to facilitate hospital discharge.

Key Concept

In patients with acute complicated pyelonephritis and Gram-negative bacteremia who achieve clinical stability and tolerate an oral diet, empiric intravenous antibiotics should be de-escalated to targeted, highly bioavailable oral antibiotics.
Rate this question

Topics

Infectious Diseases

More questions from this topic